(TXG) |
| 0 (0%) 01-13 21:09 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 24.74 |
| Resistance 1: | 21.18 |
| Pivot price: | 17.98 |
| Support 1: | 17.47 |
| Support 2: | 15.18 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.630 |
| Book Value | 6.200 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.799 |
| Profit Margin (%) | -11.89 |
| Operating Margin (%) | -21.17 |
| Return on Assets (ttm) | -8.4 |
| Return on Equity (ttm) | -10.1 |
Company news
Tue, 13 Jan 2026
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
Tue, 13 Jan 2026
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Mon, 12 Jan 2026
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
Mon, 12 Jan 2026
Why Our Analyst Turned Bullish on TXG After a Three-Year Downcycle - Hedgeye
Mon, 12 Jan 2026
TXG: Strong revenue, product innovation, and AI partnerships drive growth amid challenging capital markets - TradingView — Track All Markets
Mon, 12 Jan 2026
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
